Alzheimer Society of Canada position on aducanumab decision

Canada
read

The Alzheimer Society of Canada has been made aware of the decision by Biogen Canada Inc. to withdraw its submission of aducanumab from regulatory review by Health Canada as a treatment for people living with early stages of Alzheimer’s disease.

Alzheimer Society of Canada wordmark and identifier.

This decision will disappoint many people who had experienced positive responses to trials of the treatment, as well as those who had watched with interest and supported its approval for use in Canada.

The Alzheimer Society of Canada respects the decision made by Biogen and renews its call for additional funding for dementia research. Canada’s per capita funding commitments are far behind the funds allocated for cancer and heart disease and we rank well behind several of our G7 peers.

This must change so that new breakthroughs can be developed, tested and approved to provide hope for people living with dementia.

What is aducanumab?

In June 2021, aducanumab became the newest clinical treatment for Alzheimer’s disease in nearly two decades. A U.S. agency approved the drug that month. A European Union agency refused the drug in December 2021. Drug-maker Biogen withdrew the drug from Health Canada review in June 2022.

Learn more
Healthcare provider showing a senior woman in her care something on her tablet.

The Alzheimer Society Research Program

On this page, learn more about the Alzheimer Society Research Program, including funding opportunities for researchers, when applications open and highlights from previous ASRP funded research.

Learn more
The Alzheimer Society Research Program